Genentech Actemra meets primary endpoint in BREVACTA study
The randomised, double-blind, parallel-group study designed to assess the efficacy of treatment with Actemra 162mg SC given every two weeks versus placebo given every two weeks, both in
The US Food and Drug Administration (FDA) has granted priority review to Roche’s supplemental biologics licence application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) to treat adults with primary membranous nephropathy (pMN).
ARISg and ARISj solutions are designed for collecting, assessing, distributing and managing adverse event reporting requirements of different authorities from case entry to automatic generation of submission-ready adverse
The $582,473 grant will fund research to develop Biodel’s ultra-rapid-acting insulin product candidate at high concentrations suited to provide sufficient quantities of insulin in an external artificial pancreas